MX2021008986A - Metodos de tratamiento de un paciente con enfermedad de parkinson. - Google Patents
Metodos de tratamiento de un paciente con enfermedad de parkinson.Info
- Publication number
- MX2021008986A MX2021008986A MX2021008986A MX2021008986A MX2021008986A MX 2021008986 A MX2021008986 A MX 2021008986A MX 2021008986 A MX2021008986 A MX 2021008986A MX 2021008986 A MX2021008986 A MX 2021008986A MX 2021008986 A MX2021008986 A MX 2021008986A
- Authority
- MX
- Mexico
- Prior art keywords
- apomorphine
- treating
- parkinson
- disease
- patient
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 abstract 6
- 229960004046 apomorphine Drugs 0.000 abstract 6
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- 229960004502 levodopa Drugs 0.000 abstract 2
- 230000007659 motor function Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797660P | 2019-01-28 | 2019-01-28 | |
| US201962861077P | 2019-06-13 | 2019-06-13 | |
| US201962861067P | 2019-06-13 | 2019-06-13 | |
| PCT/US2020/015434 WO2020160005A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating a patient having parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008986A true MX2021008986A (es) | 2021-10-13 |
Family
ID=71841403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008986A MX2021008986A (es) | 2019-01-28 | 2020-01-28 | Metodos de tratamiento de un paciente con enfermedad de parkinson. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210315882A1 (https=) |
| EP (1) | EP3917502A4 (https=) |
| JP (1) | JP2022518527A (https=) |
| CA (1) | CA3121531A1 (https=) |
| MX (1) | MX2021008986A (https=) |
| WO (1) | WO2020160005A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4578461A3 (en) * | 2015-04-21 | 2025-09-03 | Sumitomo Pharma America, Inc. | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa |
| WO2023172649A1 (en) * | 2022-03-11 | 2023-09-14 | Alexza Pharmaceuticals, Inc. | Apomorphine hydrochloride trimethanolate, its polymorphs and its uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2967349B1 (fr) * | 2010-11-15 | 2013-06-14 | Oreal | Composition solide cosmetique de maquillage et/ou de soin |
| EP4578461A3 (en) * | 2015-04-21 | 2025-09-03 | Sumitomo Pharma America, Inc. | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa |
-
2020
- 2020-01-28 EP EP20749249.7A patent/EP3917502A4/en active Pending
- 2020-01-28 MX MX2021008986A patent/MX2021008986A/es unknown
- 2020-01-28 CA CA3121531A patent/CA3121531A1/en active Pending
- 2020-01-28 WO PCT/US2020/015434 patent/WO2020160005A1/en not_active Ceased
- 2020-01-28 JP JP2021543164A patent/JP2022518527A/ja active Pending
-
2021
- 2021-06-10 US US17/344,314 patent/US20210315882A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3917502A4 (en) | 2022-10-12 |
| US20210315882A1 (en) | 2021-10-14 |
| JP2022518527A (ja) | 2022-03-15 |
| WO2020160005A1 (en) | 2020-08-06 |
| EP3917502A1 (en) | 2021-12-08 |
| CA3121531A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| EP4706638A3 (en) | Methods of treating heart failure by administering omecamtiv mecarbil | |
| MX2024000049A (es) | Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo. | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2023002024A (es) | Métodos de tratamiento con modulador de miosina. | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| MX2025015137A (es) | Método para tratar la depresión usando seltorexant | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| WO2022026622A3 (en) | Treatment of viral diseases | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| PH12021550656A1 (en) | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses | |
| WO2023049534A3 (en) | Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease | |
| AU4258601A (en) | Divided dose therapies with vascular damaging activity | |
| EP4324522A3 (en) | Methods of treating fabry patients having renal impairment |